LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer

Off Science and Research

Dateline City:
KENILWORTH, N.J.

22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy

AstraZeneca and Merck’s LYNPARZA is the Only PARP Inhibitor to Demonstrate Benefit in This Setting in a Phase 3 Trial

KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United
States and Canada, today announced detailed results from the Phase 3
POLO trial evaluating LYNPARZA tablets as a first-line maintenance
monotherapy for patients with germline BRCA-mutated (gBRCAm)
metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose
disease had not progressed following platinum-based chemotherapy.

Language:
English

Contact:

Media Contacts:
Pamela Eisele
(267) 305-3558

Michael Close
(267) 305-1211

Investor Contacts:
Teri Loxam
(908) 740-1986

Michael DeCarbo
(908) 740-1807

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer »

About The Author